Immunotherapy combo aims to boost lung cancer surgery success
NCT ID NCT03694236
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tests adding the immunotherapy drug durvalumab to standard chemoradiation before surgery in people with stage III non-small cell lung cancer. About 39 participants will receive the combination, then undergo surgery to remove the tumor. Researchers will monitor side effects, survival, and immune changes in the tumor to see if this approach is safe and effective.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- durvalumab (an immunotherapy drug) combined with chemotherapy (paclitaxel and carboplatin) and radiation therapy
- What this could lead to
- If successful, this combination could improve survival and increase the chance of complete tumor removal in stage III lung cancer patients.
- What could go wrong
- This is an early-phase trial with only 39 participants, so results may not apply broadly. Adding durvalumab to chemoradiation may increase side effects like immune-related inflammation.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for POTENTIALLY RESECTABLE STAGE II/IIIA NSCLC are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Severance Hospital
RECRUITINGSeoul, Seoul, 03722, South Korea